ALK and non-small cell lung carcinoma: Among the 506 NSCLC patients who received EGFR mutation analysis in the study by Wu et al. the EGFR mutation rate was 30.04%.43 An et al. reported that the mutation rate of driver genes might differ among different histology subtypes and smoking status.44EGFR and ALK alteration is rare in PLELC.